Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes

NCT06901791 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-04-10
Last updated
2025-03-30

Condition(s) studied

GDM

Investigational drug(s) / intervention(s)

Conventional treatment and Probiotic

Conventional treatment and Probiotic: Participants will continuously take Lactobacillus rhamnosus LRa05 from the time of enrollment until delivery.

Study summary

This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Women diagnosed with gestational diabetes mellitus (GDM) at 24 weeks of gestation. Diagnostic criteria for GDM: Abnormal oral glucose tolerance test (OGTT) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol/L, 1-hour ≥ 10 mmol/L, or 2-hour ≥ 8.5 mmol/L). 2. Pregnant women aged 18 to 50 years. 3. Singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods. 4. No history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease. 5. No consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study. 6. Willing and able to provide written informed consent. 7. Capable of complying with the study protocol and follow-up requirements. Exclusion Criteria: 1. Those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results. 2. Those with other endocrine diseases or currently using medications that affect blood glucose control. 3. Those with severe cardiovascular, kidney, or liver diseases. 4. Those with immunodeficiency diseases or currently using immunosuppressive agents. 5. Those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics. 6. Those currently using other medications that may affect blood glucose control or lipid levels. 7. Those with a history of allergy to probiotics or any components of the study products. 8. Those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse. 9. Those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy. 10. Study participants deemed unsuitable by other researchers.

Primary outcome measure(s)

  • Blood glucose change — 16 weeks
    Assess and evaluate the improvement of patients' fasting blood glucose levels before the intervention begins, during the intervention, and after the intervention ends.

Trial sites (1)

FacilityCityRegionStatus
Suzhou Municipal Hospital Suzhou Jiangsu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06901791 on ClinicalTrials.gov ↗ ← All trials in China